{"Clinical Trial ID": "NCT01095003", "Intervention": ["INTERVENTION 1:", "- Vinflunine plus Capecitabine", "Vinflunine plus Capecitabine: Vinflunine 280mg/m2 perfusion of 20 minutes i.v. on day 1 of each repeated cycle every 3 weeks", "- Capecitabine 825mg/m2 per bone twice daily for 14 consecutive days starting on the first day of each repeated cycle every 3 weeks", "INTERVENTION 2:", "- Capecitabine Single agent", "Capecitabine: Capecitabine 825mg/m2 per bone twice a day for 14 consecutive days starting on the first day of each repeated cycle every 3 weeks"], "Eligibility": ["Incorporation criteria:", "Women", "- 21 years or more", "Histologically/cytologically confirmed breast carcinoma", "A locally recidivating or metastatic disease is not suitable for curative surgery or radiation therapy", "One, two or three previous chemotherapy regimens", "\u2022 Pre-treatment including both anthracycline and taxane and a patient are no longer candidates for these medicines", "A measurable or non-measurable disease according to RECIST 1.1", "Karnofsky performance score of at least 70%", "Adequate haematological, hepatic and renal functions", "ECG without clinically significant anomaly", "- Exclusion criteria:", "Clinical or known evidence of brain metastasis or leptomenal involvement", "- Pulmonary lymphangitis or symptomatic pleural effusion", "Any serious and concurrent medical disorder that is uncontrolled", "History of second primary malignancy", "\u2022 Pre-existing motor neuropathy/peripheral sensorial", "\u2022 Known history of HIV infection", "Previous treatment with capecitabine and/or vinca-alkaloids", "\u2022 History of severe hypersensitivity to or contraindication to vinca alkaloids and/or fluoropyrimidine", "known or suspected deficiency of dihydropyrimidine dehydrogenase (DPD)", "Pregnancy or lactation"], "Results": ["Performance measures:", "\u00b7 Progression Free Survival", "The PFS is defined as the time between the date of randomization and the date of the first documentation on the objective progression of the tumour (according to the Independent Response Review Committee (IARC) and on the basis of version 1.1 of the RECIST) or death due to any cause.", "The PFS was primarily analyzed in the Intent-to-Treatment (ITT) population. Patients who lost follow-up or did not experience progression or death at the time of analysis underwent progression-free survival censorship at the time of the last tumour assessment or at the date of the last contact of a follow-up that showed no progression, whichever is later.", "Time limit: Baseline up to 2 years 7 months", "Results 1:", "Title of the arm/group : Vinflunine Plus Capecitabine", "Description of the arm/group: Vinflunine plus Capecitabine: Vinflunine 280mg/m infusion of 20 minutes i.v. on day 1 of each repeated cycle every 3 weeks", "- Capecitabine 825mg/m per bone twice daily for 14 consecutive days starting on the first day of each repeated cycle every 3 weeks", "Total number of participants analysed: 384", "Median (95% confidence interval)", "Unit of measurement: Month 5.6 (5.3 to 6.3)", "Results 2:", "Title of arm/group: Capecitabine Single agent", "Description of the arm/group: Capecitabine: Capecitabine 825mg/m per bone twice daily for 14 consecutive days starting on the first day of each repeated cycle every 3 weeks", "Total number of participants analysed: 386", "Median (95% confidence interval)", "Unit of measure: month 4.3 (4.1 to 5.6)"], "Adverse Events": ["Undesirable Events 1:", "Total: 107/383 (27.94%)", "Anemia 4/383 (1.04%)", "7/383 (1.83%)", "Haemoytic anaemia 0/383 (0.00 %)", "- Leucopenia 1/383 (0.26%)", "Neutropenia 6/383 (1.57%)", "Thrombocytopenia 2/383 (0.52%)", "1/383 (0.26%)", "Cardiomyopathy 0/383 (0.00 %)", "Ear pain 0/383 (0.00 %)", "Abdominal distension 1/383 (0.26%)", "Abdominal pain 6/383 (1.57%)", "Adverse Events 2:", "Total: 85/383 (22.19 per cent)", "Anemia 3/383 (0.78%)", "Febrile neutropenia 2/383 (0.52%)", "Haemoytic anaemia 0/383 (0.00 %)", "- Leucopenia 0/383 (0.00 %)", "Neutropenia 1/383 (0.26%)", "Thrombocytopenia 1/383 (0.26%)", "- Pectoris anginaux 0/383 (0.00 %)", "Cardiomyopathy 1/383 (0.26%)", "1/383 (0.26%)", "- Abdominal distension 0/383 (0.00 %)", "Abdominal pain 3/383 (0.78%)"]}